作者
Guillaume Bailly,Maxime Robert‐Halabi,Pierre-Adrien Vion,Yves Allenbach,Baptiste Abbar,Marie Bretagne,Joe‐Elie Salem
摘要
T he question of rechallenge in cases of recovered immune checkpoint inhibitor (ICI) myocarditis is a controversial topic.Guidelines recommend against it, particularly in severe cases.[1][2][3] However, the possibility of readministering ICIs under strict surveillance rather than definitely withholding them, especially for patients who would otherwise greatly benefit, remains a clinical challenge. CASEWe report the case of a 73-year-old man diagnosed with metastatic squamous cell carcinoma of unknown primary expressing programmed cell death protein 1 (PD-1) ligand (80% positive cells) that had spread into multiple thoracoabdominal lymph nodes.One month after his cancer diagnosis, he received a first dose of pembrolizumab (anti-PD-1) in combination with carboplatin and paclitaxel (Figure 1).Almost 3 weeks later, the patient reported general fatigue and lower limb muscle weakness.Soon after, he described ocular ptosis, generalized neck flexor weakness, and progressive dyspnea, for which he was admitted for further work-up.Upon admission, his cancer treatments were held, and he was included in a prospective ICI myocarditis cohort after providing written informed consent (NCT05454527). 4 One day after admission, the patient went into complete atrioventricular block and was transferred to the cardiac intensive care unit.He underwent an urgent temporary pacemaker implantation and subsequently received a permanent leadless pacemaker.Results of coronary angiography and transthoracic echocardiography were unremarkable.The temporal trends of his creatine kinase (CK) (maximum 8,430 U/L, upper limit of normal [ULN], 200 U/L), N-terminal pro-B-type natriuretic peptide (NT-proBNP; maximum 10,222 ng/L, ULN 900 ng/L), cardiac troponin I (cTnI) (maximum 3,027 ng/L, ULN 53 ng/L), and cardiac troponin T (cTnT) (maximum 890 ng/L, ULN 14 ng/L) levels are represented in Figure 1.In the following days, his dyspnea worsened because of severe diaphragmatic involvement (confirmed by restrictive pulmonary respiratory function tests with significant worsening from sitting to supine position 4 ), requiring all-day noninvasive ventilation.An endomyocardial and a peripheral muscle biopsy were performed and showed lymphohistiocytic infiltration of both tissues, myocyte necrosis, and histopathologic findings confirming the diagnosis of ICI-induced myotoxicity.5 Repeated electromyography showed the appearance of a myopathic pattern with no associated neuromuscular junction disorder, and acetylcholine receptor autoantibodies were not detectable.6 The results of cardiac magnetic resonance imaging (MRI) were consistent with myocarditis, with the presence of septal late gadolinium enhancement and a preserved left ventricular ejection fraction (LVEF) of 67%.As shown in Figure 1, the patient was treated with ruxolitinib, a Janus kinase inhibitor (maximum